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Summary
Objective: Homocysteine has been implicated in multiple diseases that involve changes in structural tissue. In vitro studies have found that it
alters the structure of collagen cross-linking thus affecting stability and mineralization such as that occurring in bone tissue. In the present
study we considered the possible relationship between plasma homocysteine levels and the development and progression of knee osteoar-
thritis (OA).
Methods: The study question was posed in 691 men and 966 women from the original and offspring cohorts of the Framingham Osteoarthritis
Study. We divided individuals into three groups according to plasma homocysteine levels and compared their risk for the development of new
and progression of existing OA. We adjusted for potential confounders including age, body mass index, weight change, and physical activity.
Results: In the crude analysis, men in the middle homocysteine tertile were found to be at a greater risk than men in the lowest tertile for in-
cident OA [odds ratios of 1.9 (1.1e3.5)]. This result persisted after adjusting for covariates [odds: 2.0, (1.1e3.8)]. No signiﬁcant correlation was
seen in women for the development of OA. In the evaluation of progression no signiﬁcant trends were seen for both men and women.
Conclusions: Although cellular and molecular studies of homocysteine-related pathophysiology suggest a possible correlation between
plasma homocysteine levels and OA, the present clinical study did not conclusively demonstrate such an association. However, further
research is needed to explore the role of homocysteine in speciﬁc aspects of OA etiopathogenesis.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Homocysteine is a sulfur-containing amino acid involved
primarily in the metabolic pathway of methionine as well
as that of cysteine and adenosine1. Its levels in the blood
are controlled by multiple enzymes, whose activity varies
due to genetic or environmental factors. Its role in multiple
pathologic processes is evident from studies of individuals
with homocysteinurea who have extremely elevated levels
of plasma homocysteine due either to genetic mutation in
key regulatory enzymes or underlying conditions such as
kidney disease2. The normal range of plasma homocys-
teine levels for healthy adults is 5e15 mmol/liter3. However,
even moderately increased levels within the normal range
have been found to be involved in multiple disease
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766High plasma homocysteine is a risk factor for a number of
chronic illnesses including cardiovascular disease, osteo-
porosis, and impaired cognitive function as well as for preg-
nancy complications5,7e9. The role of homocysteine in
disease can be at least partially explained by its cellular
effects on various types of connective tissue10e12. High
plasma homocysteine is seen in cardiovascular disease
where it leads to increased production of collagen by the
smooth muscle cells10. Homocysteine is also involved in
pregnancy complications and adverse outcomes including
placental abruption, low birth weight, neural tube defects,
and spontaneous abortion9,13,14. Homocysteine has re-
cently been seen to play a role in osteoporosis related
bone damage. An animal model study found that rats with
elevated serum homocysteine have reduced bone quality15.
Population studies in Framingham found homocysteine
to be a predictor of hip fracture in older individuals5.
The effects of homocysteine may be linked to its involve-
ment in collagen formation. Homocysteine inhibits the syn-
thesis of insoluble collagen ﬁbrils in vitro by interfering with
normal cross-linking16. From the perspective of cartilage
homeostasis, these changes in matrix organization interfere
with chondrocyte-mediated mineralization potentially alter-
ing the function and properties of calciﬁed cartilage17.
This may be due to homocysteine mediated inhibition of ly-
sil oxidase, which catalyzes the cross-linking of collagen
molecules, a function necessary for its mineralization in
bone tissue17,18. Since osteophytes, which are marginal
767Osteoarthritis and Cartilage Vol. 17, No. 6osteocartilaginous outgrowths, emanate from osteoarthritic
joint tissue, homocysteine mediated inhibition of mineraliza-
tion may actually have a protective effect. Homocysteine
may also exert effects on bone by means other than colla-
gen reorganization. The presence of high homocysteine
leads to decreased secretion of osteocalcin and increased
osteopontin by osteoblasts19. It also stimulates osteoclast
differentiation enhancing bone resorption15,20.
Given the importance of homocysteine in bone and colla-
gen metabolism, and chondrocyte function we proposed to
explore the relation of homocysteine to osteoarthritis (OA).
OA is a disorder of multiple joint tissues characterized by
different stages of progression. Collagen is a large compo-
nent of articular cartilage, which forms the lining of the joint,
and its destruction contributes to OA. Cross-linking bands of
collagen molecules are necessary to form the stable ﬁbrils
that compose the cartilage found on articular joint surfaces
and homocysteine has been seen to disrupt the intermolec-
ular bonds of these ﬁbrils11. Changes in the collagen net-
works of joint ﬁbers observed early in the development of
OA are a potential mechanism by which homocysteine is
involved in this disease.
Homocysteine, its metabolic precursors and products
have been shown to alter various components of connec-
tive tissue, however, no studies have directly looked at
the relation between homocysteine levels and knee OA in
humans. In the present study, we used population-based
data from the Framingham OA Study to look at the predic-
tive value of homocysteine on both the development and
progression of knee OA and it association with prevalent
knee OA.MethodsSTUDY POPULATION (FRAMINGHAM OA STUDY)The Framingham Heart Study is a longitudinal population-based cohort
study established in 1948 in Framingham, Massachusetts to examine risk
factors for heart disease21. A study of the offspring of the original cohort
and their spouses was initiated in 1971. The details of this cohort have
been previously described22. The Framingham OA study, which includes
participants of the original and offspring cohorts, was developed to study
the inheritance of OA23. The present study included 691 men and 966
women from the two cohorts.
For the original cohort, baseline and follow-up visits and radiographs were
obtained at examinations 18 (1983e1985) and 22 (1992e1993), respec-
tively3. Subjects from the offspring cohort were examined between
1992e1994 and 2002e200524. Eligibility criteria for both cohorts in the pres-
ent analysis included: men and women aged 40e85 years; ambulatory (use
of assistive devices such as canes and walkers was allowed). Exclusion
criteria were: the presence of bilateral total knee replacements, and the pres-
ence of rheumatoid arthritis. The Framingham OA Study protocol involved
multiple components, one of which was a radiographic exam including post-
eroanterior (PA) ﬁxed ﬂexion25 and lateral radiographs26 of both knees.PLASMA HOMOCYSTEINENonfasting blood samples for the original cohort were collected at the 16th
biennial examination between 1979 and 1982 and stored at or below 20C.
These samples were thawed in 1997 and plasma homocysteine was mea-
sured using high-performance liquid chromatography5.
For the offspring cohort, fasting (>10 h) blood samples were collected on
the ﬁfth examination, from 1993e1994 and were frozen immediately and
stored at or below 70C27. In 1995, the samples were thawed and the total
plasma homocysteine concentrations were measured by high-performance
liquid chromatography with ﬂuorometric detection28. The coefﬁcient of varia-
tion for this assay was nine percent29.KNEE RADIOGRAPHYDuring the baseline visits, a weight-bearing fully extended radiograph of
both knees, using a standardized protocol that included outlines of the feetto keep constant the rotation of the knee at follow-up was obtained. Films
were obtained at 0 and at 6 caudad, and the best view (based on the op-
timal superimposition of the anterior and posterior margins of the medial tibial
plateau) of these two was selected for comparison at the follow-up
examination.
After the subjects completed their follow-up examination, both baseline
and follow-up radiographs were read independently by two study readers,
one a bone and joint radiologist (PA), and the other a rheumatologist (BS).
X-rays were read in a paired fashion, unblinded to sequence. Readers eval-
uated the Kellgren and Lawrence (K&L) grade30 of each knee at both time
points and evaluated individual features and whether these had changed
over the follow-up period. Each knee was evaluated for the presence of os-
teophytes and joint space narrowing (JSN) on a 0e3 scale using the OARSI
atlas31.
If there was a difference in K&L grade that led to a difference in the assig-
nation of either prevalent or incident OA status the ﬁlms were adjudicated by
a panel of three readers including the ﬁrst two and a third reader (DTF). All
adjudicated readings were arrived at by consensus of three readers using
methods previously described32. For the bone and joint radiologist, the
intra-reader kappa for K&L grade was 0.82. Inter-reader kappa was 0.74
(both P< 0.001).
Knee OA was deﬁned using the K&L grade where a score of two or higher
indicated the presence of OA. Two outcomes were considered for the pres-
ent study. Incident knee OA was deﬁned when a knee had a grade of less
than two during the baseline visit and had a K&L grade 2 at the follow-up
visit. Progression of knee OA was deﬁned when a given knee had a K&L
grade of 2 or above at baseline and at least one grade increase at the
follow-up examination32. Because they were not eligible for progression,
knees with K&L grade 4 at baseline were excluded from the study.CONFOUNDERSInformation about potential confounding variables was available from the
Framingham OA Study database. Weight was measured in kilograms with-
out shoes using a standard balance beam scale. Weight change was deﬁned
as the difference in weight between baseline and follow-up examination.
Height was measured in centimeters, without shoes, to the nearest quarter
inch. Levels of habitual physical activity were estimated based on the
number of hours spent in a typical day at different levels of activity [Physical
Activity Scale for the Elderly (PASE)]33. Information about knee injury was
derived from the response to a standard question posed at baseline,
‘‘Have you ever had a fracture or injury to a knee requiring the use of
crutches or a cane?’’ Information was obtained at the baseline for all con-
founders except ‘‘weight change’’, which involved measures at baseline
and follow-up visits.STATISTICAL ANALYSISWe combined data from Framingham original cohort and Framingham off-
spring cohort and created sex-speciﬁc tertiles of homocysteine. A total of 479
of the subjects available were removed from the ﬁnal analysis. 10 subjects
were excluded due to bilateral knee replacement, 10 because they had rheu-
matoid arthritis, 398 did not have homocysteine levels measured, and 61
were under 40 years old. The ﬁnal study group included 638 individuals
from the original and 1019 from the offspring group. Subjects were catego-
rized by tertiles of homocysteine levels to account for some of the individual
variability. We examined the relation of tertile groups of homocysteine (using
the lower tertile as the referent category) to the risk of incident radiographic
knee OA using the logistic regression model. In the multivariable regression
model, we adjusted for continuous age, dichotomous gender and knee injury
history, body mass index, weight change, and physical activity index. These
potential confounding variables were matched between the three tertiles in
an all variables in a concomitant fashion. We used generalized estimating
equations to account for correlation between two knees. Results are pre-
sented as odds ratios (OR) with 95% conﬁdence intervals of upper and lower
intervals of statistical signiﬁcance.
We adopted the same approach to assess the relation of levels of homo-
cysteine to the risk of progressive radiographic knee OA progression.Results
The baseline characteristics of the study participants are
shown in Table I. The mean age among men and women
was 60.1 and 61.2 years, respectively. Among the men,
the mean homocysteine levels were 12 3.9 for the original
cohort and 10.6 for the offspring cohort. Mean homocys-
teine levels for the women of the original and offspring
cohorts were 10.9 3.4 and 9.0 3.1, respectively. The
Table I
Characteristics of study sample (n¼ 1546 persons)
Men (n¼ 691) Women (n¼ 966)
Age in years
Mean (SD) {Range} 60.1 (10.5) {38} 61.2 (10.7) {38}
BMI kg/m2
Mean (SD) {Range) 27.3 (4.1) {18.0, 43.3} 25.9 (5.1) {14.3, 53.6}
Prevalence of Knee OA (%)* 15.4 17.3
Homocysteine mmol/liter
Mean (SD) {Range} 11.1 (3.4) {4.6, 30.8} 9.8 (3.3) {3.5, 29.0}
*Prevalence of OA measured in knees with OA over total number of knees.
768 M. Fayfman et al.: Homocysteine and knee OAcombined mean homocysteine levels among the men were
11.1 mmol/liter and among the women were 9.8 mmol/liter
(Table I). Distribution of the exposure variable (homocys-
teine) was different between men and women so the anal-
yses were performed in a gender speciﬁc manner.
The incidence of knee OA in men for three homocysteine
tertiles is shown in Table II. Before adjusting for covariates
(age, sex, body mass index, weight change, physical activ-
ity index and knee injury), we found that men in the middle
homocysteine tertile had an increased risk of developing
knee OA over the low homocysteine tertile [OR for middle
tertile, 1.9 (1.1, 3.5)]. After adjusting for the above listed co-
variates, men in the middle tertile, as in the crude analysis,
showed an increased risk of knee OA [OR for middle tertile,
2.0 (1.1, 3.8)].
The risk for incident knee OA in women of three homo-
cysteine levels is shown in Table III. In the crude analysis,
the group in the middle and high homocysteine tertile had
no increased risk of knee OA over the low tertile group.
No signiﬁcant associations were seen in the adjusted anal-
ysis as well.
We analyzed the risk of progression of knee OA in the
study subjects. Table IV shows the risk of knee OA progres-
sion in men. The OR for men in the middle and high homo-
cysteine tertiles in the crude analysis were 0.6 (0.2,1.4) and
0.7 (0.3,1.6), respectively. The results were similar for the
adjusted analysis.
Table V shows the progression of OA data for women. In
the crude analysis, the OR for the middle and high tertiles
was 1.5 (0.7, 3.4) and 1.7 (0.8, 3.8), respectively. These
ﬁndings were similar for the adjusted analysis.
In order to assess the effect of combining the original and
offspring cohorts, we did a stratiﬁed analysis of the two
groups and found that the results differed signiﬁcantly
from the combined study for the incidence of OA among
men. The offspring cohort shows a signiﬁcantly increasedTable I
Risk for incident knee OA according to homo
Low tertile Mid
Homocysteine (range mmol/liter) 4.60e8.97 9.0
Total n 398
Incident OA 25
Crude OR (95% CI) 1.0 (1.0) 1.9
Adjusted OR (95% CI)* 1.0 (1.0) 2.0
*In the Adjusted OR, potential confounding variable are matched betw
model. Potential confounders include age measured as a continuous va
low-up visits, physical activity index (PASE)32, and history of knee injury
ever had a fracture or injury to a knee requiring the use of crutches or arisk of OA for the high tertile [Crude OR: 2.6 (1.2, 5.8); Ad-
justed OR: 2.6(1.0, 6.4)] while both the original and com-
bined analysis of this group show no signiﬁcant
association. The other groups were consistent between
the stratiﬁed and combined analyses. A t test for mean ho-
mocysteine levels showed a statistically signiﬁcant differ-
ence between the two cohorts, with slightly increased
homocysteine in the original cohort 11.3 3.6 mmol/liter
compared with the offspring 9.7 3.2 mmol/liter (P< 0.001).
To further evaluate the possible threshold effect of homo-
cysteine on OA, we did a separated analysis comparing the
low tertile to the combined middle and high tertiles and
found that the results are consistent with those presented
in the paper. We also looked at prevalent OA and homocys-
teine levels ﬁnding no signiﬁcant correlations.Discussion
In the present study, we found an association between
moderately elevated homocysteine levels and increased
risk of developing OA in men. Men whose plasma homocys-
teine levels ranged between 9 mmol/liter and 11.3 mmol/liter
had a signiﬁcantly increased risk for incident OA compared
to those with homocysteine levels between 4.60 and
8.97 mmol/liter. The men in the highest tertile also appeared
to have an increased risk but these ﬁndings were not statis-
tically signiﬁcant within 95% conﬁdence interval. For the off-
spring cohort only, there did appear to be a statistically
increased incidence of OA in both the middle and high ho-
mocysteine tertiles. Given the sample size we have and risk
of disease in the low homocysteine group we observed, we
have 80% power to detect odds ratio as small as 1.6e1.9
for incident knee OA.
In the analysis for the women, we did not see a signiﬁcant
association between levels of homocysteine and incidenceI
cysteine tertile in men (n¼ 1166 knees)





(1.1e3.8) 1.7 (0.8e3.3) 0.168
een the three tertiles and calculated in a multivariable regression
riable, body mass index, weight change between baseline and fol-
based on response to the question posed at baseline, ‘‘Have you
cane?’’.
Table III
Risk for Incident Knee OA according to homocysteine tertile in women (n¼ 1587 knees)
Low tertile Middle tertile High tertile P value for trend
Homocysteine (range mmol/liter) 4.60e8.97 9.00e11.30 11.32e30.79
Total n 562 531 494
Incident OA 53 55 49
Crude OR (95% CI) 1.0 (1.0) 1.0 (0.7e1.7) 0.9 (0.6e1.5)
Adjusted OR (95% CI)* 1.0 (1.0) 0.8 (0.5e1.4) 0.7 (0.4e1.2) 0.274
*For the Adjusted OR, confounding variables were controlled in manner identical to that described in Table II.
769Osteoarthritis and Cartilage Vol. 17, No. 6of OA. It is important to note that, due to the age range of
the female subjects, the study group likely included both
pre and postmenopausal women. Sex hormones have
been seen to affect plasma homocysteine levels; estrogen
and progesterone as well as hormone replacement therapy
tend to lower levels of homocysteine34. Postmenopausal
women not taking hormone replacements have signiﬁcantly
higher plasma homocysteine levels35. Other studies looking
at the effect of homocysteine on pathology in women have
used a predominantly older population and this may be why
signiﬁcant associations were found in those cases4,5. One
limitation of the present study is that it used a single homo-
cysteine measure as a representation of the homocysteine
status of the subjects. This assumption was likely inaccu-
rate for certain subjects, such as women who had gone
through menopause shortly before or during the course of
the study. The limitation of a single homocysteine measure
extends to men who may have also had signiﬁcant unac-
counted for ﬂuctuations during the course of the study.
In our analysis of progression of knee OA, we found no
conclusive results regarding the risk for both men and
women. However, our results show an increased OR for
progression of knee OA for women with elevated homocys-
teine levels in the middle and high tertiles (Table V). In con-
trast, for men we noted a decreased OR for both of these
groups (Table IV). Given that these results were not statis-
tically signiﬁcant, we cannot include or exclude that they
may be due to chance. With the sample size of the study
population and risk of disease in the low homocysteine
group, we have 80% power to detect OR of 2.4e2.5 for
knee OA progression; therefore, our study may not have
sufﬁcient power to detect a relationship if the true OR is
less than 2.4. Using the approach employed in this study,
a larger sample size would be required to obtain sufﬁcient
power for which the relationship between homocysteine
and knee OA could reach statistical signiﬁcance.
Diet is large component of the normal variability in homo-
cysteine levels among individuals and certain substances
that affect these levels are also important in pathology.
Folate is one such dietary component that is closely in-
volved in the metabolism of homocysteine. Folate deﬁ-
ciencies reduce the activity of betaine homocysteine
methyltransferase, the enzyme that catalyzes the synthesis
of methionine from homocysteine36. Dietary supplementsTable I
Risk for knee OA progression according to hom
Low tertile Middle
Total n 57 57
Progression OA 23 16
Crude OR (95% CI) 1.0 (1.0) 0.6 (0.2
Adjusted OR (95% CI)* 1.0 (1.0) 0.4 (0.1
*For the Adjusted OR, confounding variables were controlled in mannincluding folate and cobalamin have also been demon-
strated to improve function in people with hand OA37.
Future research should consider the effect of homocys-
teine on speciﬁc aspects of OA. Homocysteine has been
found to change the collagen matrix of bone and increase
the incidence of fracture, demonstrating an effect of weak-
ening bone integrity. As osteophytes are a pathological
growth of bone that develop late in the progression of
OA, elevated plasma homocysteine may interfere with their
development. The absence of statistically signiﬁcant
ﬁndings for OA progression may be explained by a mixed
effect of homocysteine in later stages of the disease. How-
ever, a larger study population with improved power is war-
ranted in order to make any strong conclusions about the
effect of homocysteine on OA progression. In the present
study, correlating plasma homocysteine levels to both inci-
dence and progression of OA was further limited by the sin-
gle plasma homocysteine measurement available.
Furthermore, all the covariates except weight change are
also taken only at baseline, and do not reﬂect actual real
time exposure representing a possible source of error in
the present study.
There are many factors that inﬂuence homocysteine sta-
tus and, while we accounted for some of these in the pres-
ent study, the ﬁndings may be improved upon by
incorporation of nutritional factors such as vitamin supple-
mentation. The present study combined data from the orig-
inal and offspring cohorts, which employed different
protocols of obtaining and of storing blood samples that
were used for analysis. The two cohorts differed in method-
ology with regards to fasting state of the subjects as well as
the storage temperature and duration of the homocysteine
levels, potentially introducing a signiﬁcant source of error
into the study. The ﬁnding of increased risk of knee OA in
the high tertiles in the offspring cohort, which required
a 10 h fast prior to blood draws, not seen either the original
or combined groups may indicate a better control for the ef-
fect of diet on homocysteine levels. That signiﬁcant ﬁndings
were not seen across both cohorts may also suggest that
they are due simply to chance.
In sum the preliminary evidence does not suggest
a strong relationship between homocysteine and OA. How-
ever, further research is needed to explore the relation of
homocysteine to other aspects of OA etiopathogenesis.V
ocysteine tertile in men (n¼ 187 knees)




e2.1) 0.6 (0.1e1.1) 0.397
er identical to that described in Table II.
Table V
Risk for knee OA progression according to homocysteine tertile in women (n¼ 303 knees)
Low tertile Middle tertile High tertile P value for trend
Total n 69 104 130
Progression OA 16 27 36
Crude OR (95% CI) 1.0 (1.0) 1.5 (0.7e3.4) 1.7 (0.8e3.8)
Adjusted OR (95% CI)* 1.0 (1.0) 1.5 (0.7e3.5) 1.7 (0.8e3.8) 0.226
*For the Adjusted OR, confounding variables were controlled in manner identical to that described in Table II.
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